Ondansetron attenuates the activity of excitatory amino acid transporter type 3 expressed in Xenopus oocytes. 2014

Wonseok Hur, and Mi Kyoung Lee, and Hee-Pyeong Park, and Chong-Sung Kim, and Hea-Jo Yoon, and Zhiyi Zuo, and Sang-Hwan Do
Department of Anesthesiology and Pain Medicine, Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea; Department of Anesthesiology and Pain Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.

The purpose of this study was to evaluate the effect of ondansetron on excitatory amino acid transporter type 3 (EAAT3) and to elucidate the roles of protein kinase C (PKC) and phosphatidylinositol 3-kinase (PI3K) in the effect. EAAT3 was expressed in Xenopus oocytes following the injection of rat EAAT3 mRNAs. Using the two-electrode voltage clamping method, the inward currents induced by L-glutamate were measured for 1 min in the presence and absence of ondansetron (1-1000 μM). Different concentrations of L-glutamate (3-300 μM) were used to determine the kinetic characteristics of EAAT3. To identify the involvement of PKC and PI3K in the effect, oocytes were exposed to a PKC activator and to PKC inhibitors and PI3K inhibitors, and L-glutamate-induced currents were recorded. Ondansetron decreased EAAT3 activity in a dose-dependent manner. In a kinetic study, ondansetron (10 μM for 3 min) reduced Vmax, but not Km compared with the control group. The PKC activator abolished the ondansetron-induced decrease in EAAT3 activity. The PKC inhibitors (staurosporine and chelerythrine) and ondansetron had not additive or synergistic effects on EAAT3 activity. The PI3K inhibitors (wortmannin and LY294002) decreased the EAAT3 response, although there were no differences among the groups comprising ondansetron, PI3K inhibitors, and PI3K inhibitors plus ondansetron. Our results demonstrate that ondansetron attenuates EAAT3 activity and this effect seems to be mediated by PKC and PI3K.

UI MeSH Term Description Entries
D008564 Membrane Potentials The voltage differences across a membrane. For cellular membranes they are computed by subtracting the voltage measured outside the membrane from the voltage measured inside the membrane. They result from differences of inside versus outside concentration of potassium, sodium, chloride, and other ions across cells' or ORGANELLES membranes. For excitable cells, the resting membrane potentials range between -30 and -100 millivolts. Physical, chemical, or electrical stimuli can make a membrane potential more negative (hyperpolarization), or less negative (depolarization). Resting Potentials,Transmembrane Potentials,Delta Psi,Resting Membrane Potential,Transmembrane Electrical Potential Difference,Transmembrane Potential Difference,Difference, Transmembrane Potential,Differences, Transmembrane Potential,Membrane Potential,Membrane Potential, Resting,Membrane Potentials, Resting,Potential Difference, Transmembrane,Potential Differences, Transmembrane,Potential, Membrane,Potential, Resting,Potential, Transmembrane,Potentials, Membrane,Potentials, Resting,Potentials, Transmembrane,Resting Membrane Potentials,Resting Potential,Transmembrane Potential,Transmembrane Potential Differences
D008839 Microelectrodes Electrodes with an extremely small tip, used in a voltage clamp or other apparatus to stimulate or record bioelectric potentials of single cells intracellularly or extracellularly. (Dorland, 28th ed) Electrodes, Miniaturized,Electrode, Miniaturized,Microelectrode,Miniaturized Electrode,Miniaturized Electrodes
D009865 Oocytes Female germ cells derived from OOGONIA and termed OOCYTES when they enter MEIOSIS. The primary oocytes begin meiosis but are arrested at the diplotene state until OVULATION at PUBERTY to give rise to haploid secondary oocytes or ova (OVUM). Ovocytes,Oocyte,Ovocyte
D011493 Protein Kinase C An serine-threonine protein kinase that requires the presence of physiological concentrations of CALCIUM and membrane PHOSPHOLIPIDS. The additional presence of DIACYLGLYCEROLS markedly increases its sensitivity to both calcium and phospholipids. The sensitivity of the enzyme can also be increased by PHORBOL ESTERS and it is believed that protein kinase C is the receptor protein of tumor-promoting phorbol esters. Calcium Phospholipid-Dependent Protein Kinase,Calcium-Activated Phospholipid-Dependent Kinase,PKC Serine-Threonine Kinase,Phospholipid-Sensitive Calcium-Dependent Protein Kinase,Protein Kinase M,Calcium Activated Phospholipid Dependent Kinase,Calcium Phospholipid Dependent Protein Kinase,PKC Serine Threonine Kinase,Phospholipid Sensitive Calcium Dependent Protein Kinase,Phospholipid-Dependent Kinase, Calcium-Activated,Serine-Threonine Kinase, PKC
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000081082 Phosphoinositide-3 Kinase Inhibitors Agents that inhibit PHOSPHOINOSITIDE-3 KINASE activity. Phosphoinositide-3 Kinase Inhibitor,Inhibitor, Phosphoinositide-3 Kinase,Inhibitors, Phosphoinositide-3 Kinase,Kinase Inhibitor, Phosphoinositide-3,Kinase Inhibitors, Phosphoinositide-3,Phosphoinositide 3 Kinase Inhibitor,Phosphoinositide 3 Kinase Inhibitors
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014982 Xenopus laevis The commonest and widest ranging species of the clawed "frog" (Xenopus) in Africa. This species is used extensively in research. There is now a significant population in California derived from escaped laboratory animals. Platanna,X. laevis,Platannas,X. laevi

Related Publications

Wonseok Hur, and Mi Kyoung Lee, and Hee-Pyeong Park, and Chong-Sung Kim, and Hea-Jo Yoon, and Zhiyi Zuo, and Sang-Hwan Do
August 2013, European journal of pharmacology,
Wonseok Hur, and Mi Kyoung Lee, and Hee-Pyeong Park, and Chong-Sung Kim, and Hea-Jo Yoon, and Zhiyi Zuo, and Sang-Hwan Do
February 2012, European journal of pharmacology,
Wonseok Hur, and Mi Kyoung Lee, and Hee-Pyeong Park, and Chong-Sung Kim, and Hea-Jo Yoon, and Zhiyi Zuo, and Sang-Hwan Do
September 2014, European journal of pharmacology,
Wonseok Hur, and Mi Kyoung Lee, and Hee-Pyeong Park, and Chong-Sung Kim, and Hea-Jo Yoon, and Zhiyi Zuo, and Sang-Hwan Do
September 2015, European journal of pharmacology,
Wonseok Hur, and Mi Kyoung Lee, and Hee-Pyeong Park, and Chong-Sung Kim, and Hea-Jo Yoon, and Zhiyi Zuo, and Sang-Hwan Do
February 2008, Alcoholism, clinical and experimental research,
Wonseok Hur, and Mi Kyoung Lee, and Hee-Pyeong Park, and Chong-Sung Kim, and Hea-Jo Yoon, and Zhiyi Zuo, and Sang-Hwan Do
December 1990, Molecular pharmacology,
Wonseok Hur, and Mi Kyoung Lee, and Hee-Pyeong Park, and Chong-Sung Kim, and Hea-Jo Yoon, and Zhiyi Zuo, and Sang-Hwan Do
September 1988, Molecular pharmacology,
Wonseok Hur, and Mi Kyoung Lee, and Hee-Pyeong Park, and Chong-Sung Kim, and Hea-Jo Yoon, and Zhiyi Zuo, and Sang-Hwan Do
July 2008, Alcoholism, clinical and experimental research,
Wonseok Hur, and Mi Kyoung Lee, and Hee-Pyeong Park, and Chong-Sung Kim, and Hea-Jo Yoon, and Zhiyi Zuo, and Sang-Hwan Do
September 2013, European journal of pharmacology,
Wonseok Hur, and Mi Kyoung Lee, and Hee-Pyeong Park, and Chong-Sung Kim, and Hea-Jo Yoon, and Zhiyi Zuo, and Sang-Hwan Do
June 2015, European journal of pharmacology,
Copied contents to your clipboard!